Quick answer
CJC-1295 (no DAC) and ipamorelin are not competing choices: CJC-1295 is a GHRH-receptor agonist peptide, ipamorelin a ghrelin-receptor (GHS-R1a) agonist, and they feed into the same growth-hormone axis through different receptors.
- CJC-1295 (no DAC): modified GRF(1-29), a 29-residue GHRH analog; V8 product page lists 5 mg and 10 mg, ≥98% HPLC
- Ipamorelin: pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, formula C38H49N9O5 (≈ 712 Da); listed at 10 mg, ≥98% HPLC
- Why paired: two non-competing receptors let a model test combined signaling against either input alone
- Also sold as a fixed-ratio blend: CJC-1295 + Ipamorelin
- Research use: For laboratory research use only; not for human consumption.
Two entry points into one axis
For laboratory research use only; not for human consumption.
CJC-1295 and Ipamorelin are almost never discussed as competing choices; they are discussed as two different entry points into the same growth-hormone signaling axis. Understanding the comparison means understanding where each one acts along that axis, not which one outperforms the other. Growth hormone is released from pituitary somatotrophs in pulses. Hypothalamic GHRH raises the amplitude of those pulses through the GHRH receptor, ghrelin and synthetic mimetics act through a separate receptor (GHS-R1a), and somatostatin acts as the inhibitory brake. A compound's place in that circuit determines what question it can answer in a model.
CJC-1295: extending the releasing signal
CJC-1295, specifically the No-DAC variant most common in research contexts, is a synthetic analog of growth-hormone-releasing hormone (GHRH). It is also called modified GRF(1-29) because it keeps the first 29 residues of GHRH, the portion that carries receptor activity, and substitutes a few amino acids to resist enzymatic breakdown. In the sequence listed on the V8 page, position 2 is D-alanine (which blunts cleavage by dipeptidyl peptidase IV), and norleucine replaces the native methionine at position 27 (which removes an oxidation-prone residue). Its research role is to mimic the natural GHRH signal that prompts the pituitary to increase growth-hormone pulse amplitude, acting upstream at the same receptor GHRH itself would engage. Because it works by extending and amplifying an existing physiological signal rather than introducing an unrelated one, it is typically studied as a modulator of pulse characteristics (frequency, amplitude and duration) rather than as a trigger for release on its own.
The "no DAC" label matters: the Drug Affinity Complex variant carries a chemical group that binds albumin and prolongs persistence. The No-DAC form lacks it, which is why V8 describes the compound as short-acting in research models. The two forms are contrasted in CJC-1295 with DAC vs. without DAC and profiled in the CJC-1295 (no DAC) research overview.
Ipamorelin: a selective secretagogue
Ipamorelin belongs to a different peptide class entirely: a ghrelin-receptor-mimetic growth-hormone secretagogue. Rather than extending the GHRH signal, it triggers growth-hormone release directly through the ghrelin-receptor pathway, a separate route into the same axis that does not depend on GHRH-receptor engagement at all. Its defining research characteristic, relative to older and less selective secretagogues, is a comparatively high degree of receptor selectivity. The V8 product page describes it as having minimal effect on cortisol and prolactin in research models, which is the property that led to its wide use as a "clean" secretagogue tool. The compound is covered in the ipamorelin research overview, and its place among related secretagogues in hexarelin vs. ipamorelin.
Reading the axis: where each compound sits
A useful way to keep the two compounds straight is to follow the signal from top to bottom. At the top, hypothalamic GHRH binds its receptor on somatotrophs and raises intracellular cyclic AMP, which supports both growth-hormone synthesis and release. In parallel, ghrelin or a mimetic such as ipamorelin binds GHS-R1a, a G-protein-coupled receptor that signals mainly through a calcium-mobilizing pathway. Because the two intracellular routes are different, activating both is not simply double-counting one input, which is the mechanistic reason the combination is of interest in the literature on this axis. Somatostatin then limits release, so any model that reads out growth hormone is also reading the state of that inhibitory tone.
This framing also tells a researcher what each compound cannot do. CJC-1295 (no DAC), acting on the GHRH receptor, depends on the somatotroph being responsive to GHRH; ipamorelin depends on GHS-R1a expression. A cell or tissue model lacking either receptor is silent to the corresponding compound, and a negative result there says something about the model rather than the peptide. Choosing the model first, then the compound, avoids that trap.
Side-by-side comparison
| Feature | CJC-1295 (no DAC) | Ipamorelin |
|---|---|---|
| Class | GHRH analog (modified GRF 1-29) | Ghrelin-receptor agonist / GH secretagogue |
| Target receptor | GHRH receptor | GHS-R1a (ghrelin receptor) |
| Size | 29 residues | 5 residues (pentapeptide) |
| Non-standard residues | D-Ala2, norleucine at position 27 | Aib, D-2-naphthylalanine, D-Phe, C-terminal amide |
| Formula (per V8 page) | C165H269N47O46 | C38H49N9O5 |
| Listed sizes (V8) | 5 mg, 10 mg | 10 mg |
| Typical research framing | Modulates amplitude of natural GH pulses | Triggers GH release with high selectivity |
Full receptor-level detail for the pair is in the CJC-1295 & Ipamorelin research overview.
Why the stack format is common
The general rationale for studying a GHRH analog and a ghrelin-mimetic secretagogue together, rather than selecting one over the other, is explained in peptide blends and research stacks: engaging two separate, non-competing receptor pathways within the same growth-hormone system lets a research model probe whether the combined signal behaves differently, in amplitude, duration or downstream effect, from either pathway activated on its own. Because they act on two distinct receptors that both feed into growth-hormone output through different upstream mechanisms, they are frequently studied as a matched pair rather than as substitutes for one another. That premise underlies the CJC-1295 + Ipamorelin research blend, and the pairing is explained further in CJC-1295 + ipamorelin blend explained.
Choosing between singles and the blend
| If the research question is... | Better fit | Reason |
|---|---|---|
| GHRH-receptor signaling only | CJC-1295 (no DAC) alone | No second receptor input |
| Ghrelin-receptor signaling only | Ipamorelin alone | Isolates GHS-R1a |
| Combined effect at a fixed ratio | The blend | One vial, one documented ratio |
| How the ratio between the two changes the outcome | Two single-compound vials | A blend fixes the ratio |
Single products: CJC-1295 (no DAC) and ipamorelin 10 mg. Where each is sourced, see where to buy CJC-1295 (no DAC) and where to buy ipamorelin.
One more practical point concerns documentation of the paired product. A blend vial should report each peptide's identity and purity separately, because a single figure for the mixture would hide a weak component. For the blend, ask which mass was observed for each peptide and what stated amount of each is in the vial, so that the working concentration of each compound can be calculated rather than assumed.
Verification and handling differences
The two compounds behave differently on the bench, so their documentation checks differ. Ipamorelin is small enough that a mass spectrum is simple (one dominant singly charged ion near m/z 713), while the 29-residue CJC-1295 appears as a series of multiply charged ions that must be deconvoluted. In a blend, both identities and both purities must be shown separately; see CJC-1295 + ipamorelin purity testing, CJC-1295 (no DAC) purity testing and ipamorelin purity testing, plus how to read a COA and the COA page. All V8 vials are lyophilized and stored at 2–8 °C, or −20 °C for the long term, away from heat, moisture and light. For solution work, concentrations are expressed in mg/mL: 10 mg in 2 mL gives 5 mg/mL. Use the calculator and see reconstitution and storage.
Research Use Only. For laboratory research use only; not for human consumption. Not for veterinary or diagnostic purposes. This article is research education, not usage guidance.
CJC-1295 vs. ipamorelin: FAQ
Are CJC-1295 and ipamorelin alternatives to each other?
Not in the usual research framing. They act on different receptors (GHRH receptor and ghrelin receptor) within the same axis, so they are generally treated as complementary tools.
What does 'no DAC' mean?
The variant lacks the Drug Affinity Complex, an albumin-binding moiety. Without it the peptide is a short-acting modified GRF(1-29) in research models.
Why does CJC-1295 contain D-alanine and norleucine?
D-Ala at position 2 hinders cleavage by dipeptidyl peptidase IV, and norleucine replaces methionine at position 27, removing a residue prone to oxidation.
What makes ipamorelin 'selective'?
Per V8's product description it shows minimal effect on cortisol and prolactin in research models, unlike older, less selective secretagogues.
Which is more complex to verify analytically?
CJC-1295, because it is a 29-residue peptide with multiply charged mass-spec ions and more potential truncation products. Ipamorelin is a pentapeptide with a simple spectrum.
Can I vary the ratio using the blend?
No. The blend has a fixed ratio. To vary it, source the two single compounds separately.
What sizes does V8 list?
CJC-1295 (no DAC) in 5 mg and 10 mg, ipamorelin in 10 mg, and the blend in 5 mg/5 mg and 10 mg/10 mg, all at ≥98% HPLC purity per the product pages.
How do I check a lot's documentation?
Match the lot number on the vial to the certificate and use the COA page.